EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Vergleichsstudie

Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine

Donald C Simonson iD, Marcia A Testa, Ella Ekholm, Maxwell Su, Tina Vilsbøll, Serge A Jabbour, Marcus Lind

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae105 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Donald C Simonson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Glargine, Benzhydryl Compounds, Adamantane. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: AstraZeneca, Phase V Technologies, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Glycemic variability and hypoglycemia during diabetes treatment may impact therapeutic effectiveness and safety, even when glycated hemoglobin (HbA1c) reduction is comparable between therapies.

Objective

We employed masked continuous glucose monitoring (CGM) during a randomized trial of dapagliflozin plus saxagliptin (DAPA + SAXA) vs insulin glargine (INS) to compare glucose variability and patient-reported outcomes (PROs).

Design

24-week substudy of a randomized, open-label, 2-arm, parallel-group, phase 3b study.

Setting

Multicenter study (112 centers in 11 countries). Patients 283 adults with type 2 diabetes (T2D) inadequately controlled with metformin ± sulfonylurea.

Interventions

DAPA + SAXA vs INS. Main outcome measures Changes in CGM profiles, HbA1c, and PROs.

Results

Changes from baseline in HbA1c with DAPA + SAXA were similar to those observed with INS, with mean difference [95% confidence interval] between decreases of −0.12% [−0.37 to 0.12%], P = .33. CGM analytics were more favorable for DAPA + SAXA, including greater percent time in range (> 3.9 and ≤ 10 mmol/L; 34.3 ± 1.9 vs 28.5 ± 1.9%, P = .033), lower percent time with nocturnal hypoglycemia (area under the curve ≤ 3.9 mmol/L; 0.6 ± 0.5 vs 2.7 ± 0.5%, P = .007), and smaller mean amplitude of glycemic excursions (−0.7 ± 0.1 vs −0.3 ± 0.1 mmol/L, P = .017). Improvements in CGM were associated with greater satisfaction, better body weight image, less weight interference, and improved mental and emotional well-being.

Conclusion

DAPA + SAXA and INS were equally effective in reducing HbA1c at 24 weeks, but people with T2D treated with DAPA + SAXA achieved greater time in range, greater reductions in glycemic excursions and variability, less time with hypoglycemia, and improved patient-reported health outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Insulin GlargineBenzhydryl CompoundsAdamantaneGlucosidesDipeptidesBlood GlucoseGlycated HemoglobinDrug Therapy, CombinationHypoglycemic AgentsBlood Glucose Self-MonitoringHumansMaleFemaleMiddle AgedAgedHypoglycemiaTreatment OutcomeAdultPatient Reported Outcome MeasuresContinuous Glucose Monitoring

Stichwörter der Autor:innen

continuous glucose monitoringdapagliflozininsulin glarginequality of lifesaxagliptintype 2 diabetes

Substanzen

saxagliptindapagliflozinInsulin GlargineBenzhydryl CompoundsAdamantaneGlucosidesDipeptidesBlood GlucoseGlycated HemoglobinHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
  • Department of Research and Development, Phase V Technologies, Inc., Wellesley Hills, MA 02481, USA.
  • Division of Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca R&D, 431 83 Gothenburg, Sweden.
  • Clinical Research, Steno Diabetes Center Copenhagen, 2730 Herlev, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

ORCID-Profile: Donald C Simonson

Förderung

  • AstraZeneca
  • Phase V Technologies, Inc

Zitieren

APA

Simonson, D. C., Testa, M. A., Ekholm, E., Su, M., Vilsbøll, T., Jabbour, S. A., & Lind, M. (2024). Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae105

Vancouver

Simonson DC, Testa MA, Ekholm E, Su M, Vilsbøll T, Jabbour SA, et al. Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae105

BibTeX
@article{Simonson2024,
  author = {Simonson, Donald C and Testa, Marcia A and Ekholm, Ella and Su, Maxwell and Vilsbøll, Tina and Jabbour, Serge A and Lind, Marcus},
  title = {Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae105}
}
Kostenlos starten →